



DRŽITELÉ CENY MUDr. JANA BUREŠE

Kolarova, H., Tan, J., Strom, T.M., Meitinger, T., Wagner, M., & Klopstock, T. (2022). Lifetime Risk of Autosomal Recessive Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders Calculated from Genetic Databases'. *eBioMedicine* 77:103869. <https://doi.org/10.1016/j.ebiom.2022.103869>.

IF 2021: 11,205; Q1 (Medicine, Research & Experimental)

Benek, O., Korabecny, J., & Soukup, O. (2020). A Perspective on Multi-target Drugs for Alzheimer's Disease. *Trends in Pharmacological Sciences*, 41(7), 434-445. <https://doi.org/10.1016/j.tips.2020.04.008>.

IF 2019: 13,503; Q1 (Pharmacology)

Tesar, A., Matej, R., Kukal, J., Johanidesova, S., Rektorova, I., Vyhnalek, M., Keller, J., Eliasova, I., Parobkova, E., Smetakova, M., Musova, Z., & Rusina, R. (2019). Clinical Variability in P102L Gerstmann-Sträussler-Scheinker Syndrome. *Annals of Neurology*, 86(5), 643-652. <https://doi.org/10.1002/ana.25579>.

IF 2018: 9,496; Q1 (Neurosciences; Clinical neurology)

Petrasek, T., Vojtechova, I., Lobellova, V., Popelikova, A., Janikova, M., Brozka, H., Houdek, P., Sladek, M., Sumova, A., Kristofikova, Z., Vales, K., & Stuchlík, A. (2018). The McGill Transgenic Rat Model of Alzheimer's Disease Displays Cognitive and Motor Impairments, Changes in Anxiety and Social Behavior, and Altered Circadian Activity. *Frontiers in Aging Neuroscience*, 10, 250. <https://doi.org/10.3389/fnagi.2018.00250>

IF 2018: 3,633; Q2 (Geriatrics & gerontology; Neurosciences)

Cermakova, P., Muller, M., Armstrong, A. C., Religa, D., Bryan, R. N., Lima, J. A. C., & Launer, L. J. (2017). Subclinical Cardiac Dysfunction and Brain Health in Midlife: CARDIA (Coronary Artery Risk Development in Young Adults) Brain Magnetic Resonance Imaging Substudy. *Journal of the American Heart Association*, 6(12), e006750. <https://doi.org/10.1161/JAHA.117.006750>

IF 2017: 4,450; Q2 (Cardiac & cardiovascular systems)

Vyklicky, V., Smejkalova, T., Krausova, B., Balik, A., Korinek, M., Borovska, J., Horak, M., Chvojkova, M., Kleteckova, L., Vales, K., Cerny, J., Nekardova, M., Chodounska, H., Kudova, E., & Vyklicky, L. (2016). Preferential Inhibition of Tonically over Phasically Activated NMDA Receptors by Pregnane Derivatives. *Journal of Neuroscience*, 36(7), 2161–2175. <https://doi.org/10.1523/JNEUROSCI.3181-15.2016>

IF 2016: 5,988; Q1 (Neurosciences)

Rohan, Z., Rahimi, J., Weis, S., Kapas, I., Auff, E., Mitrovic, N., Liberski, P. P., Sikorska, B., Matej, R., & Kovacs, G. G. (2015). Screening for α -synuclein immunoreactive neuronal inclusions in the hippocampus allows identification of atypical MSA (FTLD-synuclein). *Acta Neuropathologica*, 130(2), 299–301. <https://doi.org/10.1007/s00401-015-1455-7>

IF 2015: 11,360; Q1 (Clinical neurology; Neurosciences; Pathology)

Nepovimova, E., Uliassi, E., Korabecny, J., Peña-Altamira, L. E., Samez, S., Pesaresi, A., Garcia, G. E., Bartolini, M., Andrisano, V., Bergamini, C., Fato, R., Lamba, D., Roberti, M., Kuca, K., Monti, B., & Bolognesi, M. L. (2014). Multitarget Drug Design Strategy: Quinone–Tacrines Hybrids Designed To Block Amyloid- β Aggregation and To Exert Anticholinesterase and Antioxidant Effects. *Journal of Medicinal Chemistry*, 57(20), 8576–8589. <https://doi.org/10.1021/jm5010804>

IF 2014: 5,447; Q1 (Medicinal chemistry)

Janíčková, H., Rudajev, V., Zimčík, P., Jakubík, J., Tanila, H., El-Fakahany, E. E., & Doležal, V. (2013). Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid β 1–42. *Neuropharmacology*, 67, 272–283. <https://doi.org/10.1016/j.neuropharm.2012.11.014>

IF 2013: 4,819; Q1 (Neurosciences; Pharmacology & pharmacy)

Nedelska, Z., Andel, R., Laco, J., Vlcek, K., Horinek, D., Lisy, J., Sheardova, K., Bures, J., & Hort, J. (2012). Spatial navigation impairment is proportional to right hippocampal volume. *Proceedings of the National Academy of Sciences*, 109(7), 2590–2594. <https://doi.org/10.1073/pnas.1121588109>

IF 2012: 9,737; Q1 (Multidisciplinary sciences)

Skoumalová, A., Ivica, J., Šantorová, P., Topinková, E., & Wilhelm, J. (2011). The lipid peroxidation products as possible markers of Alzheimer's disease in blood. *Experimental Gerontology*, 46(1), 38–42. <https://doi.org/10.1016/j.exger.2010.09.015>

IF 2011: 3,741; Q1 (Geriatrics & gerontology)